Lymphoplasmacytic lymphoma primary prevention
Lymphoplasmacytic lymphoma Microchapters |
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Lymphoplasmacytic lymphoma primary prevention On the Web |
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma primary prevention |
Risk calculators and risk factors for Lymphoplasmacytic lymphoma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
Primary prevention of lymphoplasmacytic lymphoma depends on the type of modifiable risk factor causing the disease such as Hepatitis C, HIV, Rickettsiosis, Hay fever, Human T-lymphotrophic virus type 1 infection, Epstein-Barr virus infection, environmental factors, history of Helicobacter pylori infection, history of immunosuppressant drug therapy after an organ transplant, diet rich in meat and fat and history of past treatment for Hodgkin lymphoma.
Primary Prevention
Primary prevention of lymphoplasmacytic lymphoma depends on the type of risk factor causing the disease.[1]
Modifiable risk factors:
- Hepatitis C[2][3][4][5][6]
- HIV
- Rickettsiosis
- Hay fever
- Human T-lymphotrophic virus type 1 infection
- Epstein-Barr virus infection
- Environmental factors:[7]
- Occupational (Farming)
- Pesticides
- Paint
- Rubber dyes
- Benzene
- Coal dust
- Leather manufacturing
- Wood dust
- Organic solvents
- History of Helicobacter pylori infection
- History of immunosuppressant drug therapy after an organ transplant
- Diet rich in meat and fat
- History of past treatment for Hodgkin lymphoma
References
- ↑ Waldenström's macroglobulinemia. American Cancer Society. (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-prevention Accessed on November 11, 2015
- ↑ Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O (2008). "Chronic immune stimulation and subsequent Waldenström macroglobulinemia". Arch Intern Med. 168 (17): 1903–9. doi:10.1001/archinternmed.2008.4. PMC 2670401. PMID 18809818.
- ↑ de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM; et al. (2008). "Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium". Clin Gastroenterol Hepatol. 6 (4): 451–8. doi:10.1016/j.cgh.2008.02.011. PMC 3962672. PMID 18387498.
- ↑ Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I; et al. (2010). "Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia". J Natl Cancer Inst. 102 (8): 557–67. doi:10.1093/jnci/djq043. PMC 2857799. PMID 20181958.
- ↑ Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J; et al. (2008). "Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium". Blood. 111 (8): 4029–38. doi:10.1182/blood-2007-10-119974. PMC 2288717. PMID 18263783.
- ↑ Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH; et al. (2006). "Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia". J Natl Cancer Inst. 98 (18): 1321–30. doi:10.1093/jnci/djj361. PMID 16985251.
- ↑ Vajdic CM, Landgren O, McMaster ML, Slager SL, Brooks-Wilson A, Smith A; et al. (2014). "Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project". J Natl Cancer Inst Monogr. 2014 (48): 87–97. doi:10.1093/jncimonographs/lgu002. PMC 4155457. PMID 25174029.